Olema Oncology (OLMA) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
10 Nov, 2026Palazestrant trials
OPERA-01 compares palazestrant with fulvestrant or exemestane after CDK4/6 inhibitor plus AI progression; top-line results expected in Q1 2027.
Post-CDK4/6 market estimated at $5B annually: ESR1-mutant patients represent ~$2B and wild type ~$3B; phase II median PFS was 7.3 months and 5.5 months, respectively.
OPERA-02 is a 1,000-patient first-line trial of ribociclib plus palazestrant versus ribociclib plus letrozole; enrollment is robust.
OPERA-02 could add patients if SERENA-4 shows a stronger-than-historical control arm; potential resizing may affect the readout forecast.
First-line opportunity estimated at $10B+; palazestrant plus ribociclib showed median PFS over one year post-CDK4/6 plus AI in phase II, without enhanced toxicity or dose modifications.
Clinical rationale and upcoming data
Palazestrant is a complete estrogen receptor antagonist and degrader; high exposure and sustained receptor blockade are cited as rationale for activity in ESR1 wild-type disease.
OPERA-01 analyzes ESR1-mutant and wild-type subsets independently; either subset meeting its hazard-ratio and critical P-value criteria could make the trial positive.
Q1 2027 disclosure is expected to report trial outcomes in both ESR1 subsets; fuller details are planned for a subsequent medical meeting.
PERSEVERA missed its hazard-ratio threshold by a few hundredths but showed a favorable trend and ~5-month PFS difference; its treatment-free-interval criterion is not used in OPERA-02.
San Antonio presentations will include palazestrant combinations with everolimus and atirmociclib; everolimus data will include ESR1-mutant and wild-type results.
KAT6 inhibitor program
OP-3136 showed single-agent activity in metastatic ER-positive, HER2-negative breast cancer and castration-resistant prostate cancer; dose escalation reached 80 mg daily, with MTD still undetermined.
Fulvestrant combination dose-escalation data, including early response and tolerability, are planned for San Antonio; palazestrant combination data are expected mid-2027.
NUBEQA combination enrollment in prostate cancer is expected to begin in the coming months; earliest shareable data are expected later in 2027.
Narrower KAT selectivity is hypothesized to reduce cytopenias; dysgeusia is a side effect seen across this class of agents.
Latest events from Olema Oncology
- Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026